Yanwei Zhang

B. Han, Yu Dong, Xueyan Zhang, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The centromere-associated protein CENPU promotes cell proliferation, migration, and invasiveness in lung adenocarcinoma.

Huimin Wang, H. Zhong, Jun Lu, 2022, Cancer letters.

ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients

Huimin Wang, Jun Lu, Y. Lou, 2021, Frontiers in Genetics.

Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies

B. Han, Yu Dong, H. Zhong, 2020, International journal of cancer.

The Survival Benefit for Optimal Glycemic Control in Advanced Non-Small Cell Lung Cancer Patients With Preexisting Diabetes Mellitus

B. Han, Lin Wang, Jun Lu, 2021, Frontiers in Oncology.

Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas

B. Han, Jun Lu, R. Qiao, 2018, Cancer.

Clinical characteristics and prognostic factors of surgically resected combined small cell lung cancer: a retrospective study.

Xiao-hong Fan, Yanwei Zhang, T. Chu, 2020, Lung cancer.

EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.

B. Han, Bo Jin, Xueyan Zhang, 2016, Lung cancer.

EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study.

B. Han, Y. Lou, Jianlin Xu, 2020, Clinical lung cancer.

Different characteristics and survival in non‐small cell lung cancer patients with primary and acquired EGFR T790M mutation

B. Han, Yu Dong, Jun Lu, 2019, International journal of cancer.

Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib

B. Han, R. Qiao, Jianlin Xu, 2019, Targeted Oncology.

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China

B. Han, Bo Jin, Xueyan Zhang, 2016, Journal of Cancer Research and Clinical Oncology.

Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?

B. Han, Xueyan Zhang, Huimin Wang, 2018, Lung cancer.

Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma

B. Han, Bo Jin, Yu Dong, 2014, Tumor Biology.

EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation

B. Han, Bo Jin, Xueyan Zhang, 2016, Scientific Reports.

Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation

B. Han, Bo Jin, Xueyan Zhang, 2016, Scientific Reports.

Combination of chemotherapy and gefitinib as first‐line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial

B. Han, Bo Jin, Yu Dong, 2017, International journal of cancer.

MDC and BLC are independently associated with the significant risk of early stage lung adenocarcinoma

B. Han, Xueyan Zhang, Huimin Wang, 2016, Oncotarget.

Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study

B. Han, Xueyan Zhang, Huimin Wang, 2020, Targeted Oncology.

New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer

B. Han, Jianlin Xu, Yanwei Zhang, 2020, Journal of Cancer Research and Clinical Oncology.

Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non‐small‐cell lung cancer patients with EGFR mutations

B. Han, Bo Jin, Xueyan Zhang, 2017, International journal of cancer.

CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients

B. Han, Xueyan Zhang, Huimin Wang, 2020, Frontiers in Oncology.

OCT4&SOX2‐specific cytotoxic T lymphocytes plus programmed cell death protein 1 inhibitor presented with synergistic effect on killing lung cancer stem‐like cells in vitro and treating drug‐resistant lung cancer mice in vivo

B. Han, Xueyan Zhang, Huimin Wang, 2018, Journal of cellular physiology.

Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.

B. Han, R. Qiao, Jianlin Xu, 2019, Clinical lung cancer.

Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update

Hongyu Liu, Xueyan Zhang, Huimin Wang, 2022, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer

B. Han, Bo Jin, Xueyan Zhang, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and efficacy of anlotinib in combination with standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A multi-center, prospective study (ACTION-2).

Wei Zhang, Yu Dong, F. Qian, 2022, Lung cancer.

Clinicopathological characteristics and gene analysis of pulmonary granular cell tumor in three cases and a systematic review

Xueyan Zhang, Feng Li, Yanwei Zhang, 2020, Translational cancer research.

The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China

B. Han, Bo Jin, Xueyan Zhang, 2016, OncoTargets and therapy.

Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review

B. Han, Xueyan Zhang, Jun Lu, 2018, Targeted Oncology.

Multi-Omics Signatures Identification for LUAD Prognosis Prediction Model Based on the Integrative Analysis of Immune and Hypoxia Signals

Huimin Wang, H. Zhong, Jun Lu, 2022, Frontiers in Cell and Developmental Biology.

Prediction of lymph node status in completely resected IIIa/N2 small cell lung cancer: importance of subcarinal station metastases

B. Han, R. Qiao, Y. Lou, 2019, Journal of Cardiothoracic Surgery.